Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2009

Conditions
HIV InfectionsTuberculosis
Interventions
DRUG

HAART containing nevirapine

Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.

Trial Locations (6)

10330

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok

11000

Bamrasnaradura Institute, Nonthaburi

Central Chest Hospital, Nonthaburi

57000

Chiangrai Hospital, Chiang Rai

Mae Chan Hospital, Chiang Rai

Phan Hospital, Chiang Rai

All Listed Sponsors
collaborator

other sponsors:Japanese MOPH

UNKNOWN

collaborator

Labor and Welfare

UNKNOWN

collaborator

Thai MOPH

UNKNOWN

collaborator

Thai GPO

UNKNOWN

collaborator

Bamrasnaradura Infectious Diseases Institute

OTHER_GOV

collaborator

Chiang Rai Hospital

OTHER

collaborator

King Chulalongkorn Memorial Hospital

OTHER

collaborator

Central General Chest Institute

UNKNOWN

collaborator

The Research Institute of Tuberculosis (Japan)

UNKNOWN

lead

The HIV Netherlands Australia Thailand Research Collaboration

OTHER

NCT00476853 - Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy | Biotech Hunter | Biotech Hunter